Atossa Therapeutics Inc (NASDAQ: ATOS) on Tuesday, plunged -5.47% from the previous trading day, before settling in for the closing price of $0.92. Within the past 52 weeks, ATOS’s price has moved between $0.77 and $2.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 9.72%. With a float of $125.75 million, this company’s outstanding shares have now reached $125.80 million.
The extent of productivity of a business whose workforce counts for 12 workers is very important to gauge. In terms of profitability, gross margin is -27.78%, operating margin of -163827.78%, and the pretax margin is -149505.56%.
Atossa Therapeutics Inc (ATOS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Atossa Therapeutics Inc is 0.04%, while institutional ownership is 21.86%. The most recent insider transaction that took place on Apr 10 ’24, was worth 44,250. In this transaction Director of this company bought 25,000 shares at a rate of $1.77, taking the stock ownership to the 25,000 shares.
Atossa Therapeutics Inc (ATOS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 9.72% per share during the next fiscal year.
Atossa Therapeutics Inc (NASDAQ: ATOS) Trading Performance Indicators
Atossa Therapeutics Inc (ATOS) is currently performing well based on its current performance indicators. A quick ratio of 13.30 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.27 in one year’s time.
Technical Analysis of Atossa Therapeutics Inc (ATOS)
The latest stats from [Atossa Therapeutics Inc, ATOS] show that its last 5-days average volume of 0.9 million was superior to 0.8 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 11.83%. Additionally, its Average True Range was 0.07.
During the past 100 days, Atossa Therapeutics Inc’s (ATOS) raw stochastic average was set at 1.77%, which indicates a significant decrease from 6.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.73% in the past 14 days, which was higher than the 53.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1837, while its 200-day Moving Average is $1.3583. Now, the first resistance to watch is $0.9221. This is followed by the second major resistance level at $0.9701. The third major resistance level sits at $1.0011. If the price goes on to break the first support level at $0.8431, it is likely to go to the next support level at $0.8121. The third support level lies at $0.7641 if the price breaches the second support level.
Atossa Therapeutics Inc (NASDAQ: ATOS) Key Stats
Market capitalization of the company is 109.97 million based on 125,801K outstanding shares. Right now, sales total 0 K and income totals -30,090 K. The company made 0 K in profit during its latest quarter, and -7,230 K in sales during its previous quarter.
